Department of Radiology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Japan.
Ann Nucl Med. 2013 Jan;27(1):78-83. doi: 10.1007/s12149-012-0647-7. Epub 2012 Aug 23.
The aim of this study was to report our early experience with (18)F-fluoride PET/CT for detecting lesions and evaluate the usefulness of this modality in the assessment of multiple myeloma (MM).
(18)F-fluoride PET/CT and (99m)Tc-MDP bone scintigraphy (BS) studies from 7 myeloma patients (4 male and 3 female, mean age 55 years) diagnosed according to standard criteria were reviewed retrospectively. Two reviewers visually and quantitatively analyzed the images and recorded their findings after reaching a consensus. Diagnostic certainty regarding the presence or absence of myeloma lesions was evaluated according to the reference standard consisting of whole-body magnetic resonance imaging and whole-body X-ray.
A total of 93 affected areas were definite according to the reference standard. Of these, 83 affected areas (89 %) were identified on (18)F-fluoride PET/CT, whereas 54 affected areas (58 %) were found on BS. Mean SUVmax in the affected areas was 9.8 ± 3.2 (standard deviation) ranging from 5.0 to 21.2. A total of s17 lesions with bone fracture were also detected by (18)F-fluoride PET/CT and 2 lesions (12 %) were negative on BS.
Our result showed that (18)F-fluoride PET was a possible modality to detect areas of lesions in patients with MM.
本研究旨在报告我们在检测病变方面应用（18）F-氟化物 PET/CT 的早期经验，并评估该方法在多发性骨髓瘤（MM）评估中的应用价值。
回顾性分析了 7 例 MM 患者（4 名男性，3 名女性，平均年龄 55 岁）的（18）F-氟化物 PET/CT 和（99m）Tc-MDP 骨扫描（BS）资料。两名观察者在达成共识后，对图像进行了视觉和定量分析，并记录了他们的发现。根据包括全身磁共振成像和全身 X 射线检查在内的参考标准，评估了有无骨髓瘤病变的诊断确定性。
根据参考标准，共有 93 个明确的受累区域。其中，（18）F-氟化物 PET/CT 发现 83 个受累区域（89%），BS 发现 54 个受累区域（58%）。受累区域的平均 SUVmax 为 9.8±3.2（标准差），范围为 5.0 至 21.2。（18）F-氟化物 PET/CT 还检测到了总共 17 个伴骨折的病变，BS 有 2 个病变（12%）为阴性。
我们的结果表明，（18）F-氟化物 PET 可能是一种检测 MM 患者病变部位的方法。
